Legend Biotech Corporation (NASDAQ:LEGN) shares raced in Friday trading.
Legend Biotech, last month, announced submission of European marketing authorization application for BCMA CAR-T therapy ciltacabtagene autoleucel for treatment of relapsed and/or refractory multiple myeloma.
This week, the company announced that 15 abstracts have been accepted at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2021 Virtual Congress, including new and updated data from the CARTITUDE clinical development program being led by Janssen Research & Development, LLC (Janssen) for the investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, ciltacabtagene autoleucel (cilta-cel).
"The Legend Biotech team, together with our collaborator Janssen, look forward to sharing the updated efficacy and longer-term safety data for cilta-cel," said CEO Ying Huang.
"These exciting data and a wide range of other abstracts highlight our continued commitment and efforts to developing innovative treatments that will make a difference in the lives of those living with multiple myeloma."
For the first time, data from Cohort A of the CARTITUDE-2 study evaluating the safety and efficacy of cilta-cel in patients with progressive multiple myeloma who have received one to three prior lines of therapy, will be presented, being featured as a poster presentation at ASCO (Abstract #8013) and in an oral presentation at EHA (Abstract # S190).
Poster presentations at both meetings will provide additional efficacy and safety information with cilta-cel in comparison to standard of care therapies and neurological adverse event mitigation measures.
LEGN shares sprang 63 cents, or 2%, to $31.65.
Related Stories
